Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 488

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 488
---
2024.

The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands):

|                                         |     | December 31,2024 |        |   |
|:----------------------------------------|:----|:-----------------|-------:|:--|
| Beginning Balance as of October 8, 2024 |     | $                | 42,740 |   |
| Conversion of Tranche B notes           |     |                  | (9,255 | ) |
| Repayment of Tranche B Notes            |     |                  | (3,283 | ) |
| Change in fair value of Tranche B Notes |     |                  | (6,641 | ) |
| Ending Balance as of December 31, 2024  |     | $                | 23,560 |   |

Aggregate principal repayments for the Company’s outstanding debt will be $ 47.7 million and $ 19.5 million in 2025 and 2026, respectively.

ZTlido Royalty Purchase Agreement

On October 8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8 % of all aggregate net sales worldwide (the “ZTlido Purchased Receivables”) with respect to ZTlido, SP-103 and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter.

In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement, the aggregate purchase price for the ZTlido Purchased Receivables was $ 5.0 million (net of expenses of the ZTlido Royalty Purchasers). The ZTlido Royalty Investors paid to Scilex Pharma an aggregate amount equal to $ 2.5 million minus the expenses of the ZTlido Royalty Investors and Oramed paid to Scilex Pharma an amount equal to $